Dendritic cells and immunity against cancer

Journal of Internal Medicine

Volumn 269, Issue 1, 2011, Pages 64-73

  Palucka, K ^a,b,c   Ueno, H ^a   Fay, J ^a,b   Banchereau, J ^a,c  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Dendritic cells; T cells; Vaccines

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; CANCER PATIENT; CELL SUBPOPULATION; CONFERENCE PAPER; DENDRITIC CELL; DRUG EFFICACY; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MEMORY T LYMPHOCYTE; METASTASIS; MICROENVIRONMENT; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT;

EID: 78650199162     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02317.x     Document Type: Conference Paper

References (119)

1. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
3. Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-15.
4. Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A 1996; 93: 4529-36.
5. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor- specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4: 1321-4.
6. Spisek R, Kukreja A, Chen LC et al. Frequent and specific immunity to the embryonal stem cell associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204: 831-40.
7. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
8. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65.
9. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-82.
10. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative diseases. Immunol Rev 1997; 157: 217-22.
11. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 117: 1204-12.
12. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV- associated lymphoma. N Engl J Med 1994; 331: 679-80.
13. Yee C, Thompson JA, Byrd D et al. Adoptive T cell therapy using antigen- specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99: 16168-73.
14. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4.
15. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-26.
16. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus- like particle vaccine against human papillomavirus types 16 and 18: follow- up from a randomised control trial. Lancet 2006; 367: 1247-55.
17. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630-41.
18. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008; 14: 623-8.
19. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117.
20. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
21. Hodi FS, O'Day SJ, McDermott DF et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363: 711-23.
22. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double- blind, placebo- controlled, phase 3 trials of active cellular immunotherapy with sipuleucel- T in advanced prostate cancer. Cancer 2009; 115: 3670-9.
23. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral- based PSA- targeted immunotherapy in metastatic castration- resistant prostate cancer. J Clin Oncol 2010; 28: 1099-105.
24. Schwartzentruber DJ, Lawson D, Richards J et al. A phase III multi- institutional randomized study of immunization with the gp100: 209-217 (210M) peptide followed by high- dose IL- 2 compared with high- dose IL- 2 alone in patients with metastatic melanoma. J Clin Oncol 2009; 27: 18s.
25. Schuster SJ, Neelapu SS, Gause BL et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. ASCO Meeting Abstract 2009.
26. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-83.
27. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220: 129-50.
28. Schuler G, Schuler- Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138-47.
29. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti- CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-13.
30. Day CL, Kaufmann DE, Kiepiela P et al. PD- 1 expression on HIV- specific T cells is associated with T- cell exhaustion and disease progression. Nature 2006; 443: 350-4.
31. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-80.
32. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
33. Volkmann A, Zal T, Stockinger B. Antigen- presenting cells in the thymus that can negatively select MHC class II- restricted T cells recognizing a circulating self antigen. J Immunol 1997; 158: 693-706.
34. Zal T, Volkmann A, Stockinger B. Mechanisms of tolerance induction in major histocompatibility complex class II- restricted T cells specific for a blood- borne self- antigen. J Exp Med 1994; 180: 2089-99.
35. Fairchild PJ, Austyn JM. Thymic dendritic cells: phenotype and function. Int Rev Immunol 1990; 6: 187-96.
36. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 2004; 20: 695-705.
37. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10- producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-22.
38. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11: 7-13.
39. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non- coding DNA elements in the Foxp3 gene in regulatory T- cell fate. Nature 2010; 463: 808-12.
40. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL- 10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2: 725-31.
41. Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 1996; 157: 1406-14.
42. Brimnes MK, Bonifaz L, Steinman RM, Moran TM. Influenza virus- induced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J Exp Med 2003; 198: 133-44.
43. Jego G, Pascual V, Palucka AK, Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 2005; 8: 124-39.
44. Qi H, Egen JG, Huang AY, Germain RN. Extrafollicular activation of lymph node B cells by antigen- bearing dendritic cells. Science 2006; 312: 1672-6.
45. Zhong G, Reis e Sousa C, Germain RN. Antigen- unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen- major histocompatibility class II complexes after soluble protein exposure in vivo or in vitro. J Exp Med 1997; 186: 673-82.
46. Wykes M, Pombo A, Jenkins C, MacPherson GG. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T- dependent response. J Immunol 1998; 161: 1313-9.
47. Bergtold A, Desai DD, Gavhane A, Clynes R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 2005; 23: 503-14.
48. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 2009; 9: 15-27.
49. Siegal FP, Kadowaki N, Shodell M et al. The nature of the principal type 1 interferon- producing cells in human blood. Science 1999; 284: 1835-7.
50. Liu YJ. IPC: professional type 1 interferon- producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275-306.
51. Matsui T, Connolly JE, Michnevitz M et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182: 6815-23.
52. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA. Normal human dermis contains distinct populations of CD11c+BDCA- 1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 2007; 117: 2517-25.
53. Klechevsky E, Morita R, Liu M et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29: 497-510.
54. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin- expressing dendritic cells. Nat Rev Immunol 2008; 8: 935-47.
55. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9: 679-91.
56. Caux C, Massacrier C, Vanbervliet B et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte- macrophage colony- stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997; 90: 1458-70.
57. Schmitt N, Morita R, Bourdery L et al. Human dendritic cells induce the differentiation of interleukin- 21- producing T follicular helper- like cells through interleukin- 12. Immunity 2009; 31: 158-69.
58. Dubois B, Massacrier C, Vanbervliet B et al. Critical role of IL- 12 in dendritic cell- induced differentiation of naive B lymphocytes. J Immunol 1998; 161: 2223-31.
59. Bachem A, Guttler S, Hartung E et al. Superior antigen cross- presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207: 1273-81.
60. Crozat K, Guiton R, Contreras V et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207: 1283-92.
61. Jongbloed SL, Kassianos AJ, McDonald KJ et al. Human CD141+ (BDCA- 3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross- presents necrotic cell antigens. J Exp Med 2010; 207: 1247-60.
62. Poulin LF, Salio M, Griessinger E et al. Characterization of human DNGR- 1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207: 1261-71.
63. Mohamadzadeh M, Berard F, Essert G et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001; 194: 1013-20.
64. Dubsky P, Saito H, Leogier M et al. IL- 15- induced human DC efficiently prime melanoma- specific naive CD8(+) T cells to differentiate into CTL. Eur J Immunol 2007; 37: 1678-90.
65. Mailliard RB, Wankowicz- Kalinska A, Cai Q et al. alpha- type- 1 polarized dendritic cells: a novel immunization tool with optimized CTL- inducing activity. Cancer Res 2004; 64: 5934-7.
66. Fujita M, Zhu X, Ueda R et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells- - significant roles of CXCL10. Cancer Res 2009; 69: 1587-95.
67. Giermasz AS, Urban JA, Nakamura Y et al. Type- 1 polarized dendritic cells primed for high IL- 12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 2009; 58: 1329-36.
68. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC- 205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196: 1627-38.
69. Bonifaz LC, Bonnyay DP, Charalambous A et al. In vivo targeting of antigens to maturing dendritic cells via the Dec- 205 receptor improves T cell vaccination. J Exp Med 2004; 199: 815-24.
70. Sancho D, Mourao-Sa D, Joffre OP et al. Tumor therapy in mice via antigen targeting to a novel, DC- restricted C- type lectin. J Clin Invest 2008; 118: 2098-110.
71. Wei H, Wang S, Zhang D et al. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res 2009; 15: 4612-21.
72. Caminschi I, Lahoud MH, Shortman K. Enhancing immune responses by targeting antigen to DC. Eur J Immunol 2009; 39: 931-8.
73. Flacher V, Sparber F, Tripp CH, Romani N, Stoitzner P. Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunol Immunother 2009; 58: 1137-47.
74. Tacken PJ, de Vries IJ, Gijzen K et al. Effective induction of naive and recall T- cell responses by targeting antigen to human dendritic cells via a humanized anti- DC- SIGN antibody. Blood 2005; 106: 1278-85.
75. Birkholz K, Schwenkert M, Kellner C et al. Targeting of DEC- 205 on human dendritic cells results in efficient MHC class II- restricted antigen presentation. Blood 2010; 116: 2277-85.
76. Bozzacco L, Trumpfheller C, Siegal FP et al. DEC- 205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A 2007; 104: 1289-94.
77. Klechevsky E, Flamar AL, Cao Y et al. Cross- priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010; 116: 1685-97.
78. Bell D, Chomarat P, Broyles D et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999; 190: 1417-26.
79. Aspord C, Pedroza- Gonzalez A, Gallegos M et al. Breast cancer instructs dendritic cells to prime interleukin 13- secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007; 204: 1037-47.
80. DeNardo DG, Barreto JB, Andreu P et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
81. Berzofsky JA, Terabe M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol Immunother 2008; 57: 1679-83.
82. Kukreja A, Hutchinson A, Dhodapkar K et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006; 203: 1859-65.
83. Bahlis NJ, King AM, Kolonias D et al. CD28- mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007; 109: 5002-10.
84. Treilleux I, Blay JY, Bendriss- Vermare N et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10: 7466-74.
85. Hartmann E, Wollenberg B, Rothenfusser S et al. Identification and functional analysis of tumor- infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-87.
86. Cao W, Bover L, Cho M et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 2009; 206: 1603-14.
87. Wei S, Kryczek I, Zou L et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005; 65: 5020-6.
88. Coukos G, Benencia F, Buckanovich RJ, Conejo- Garcia JR. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 2005; 92: 1182-7.
89. Curiel TJ, Cheng P, Mottram P et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64: 5535-8.
90. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8- activated inflammatory dendritic cells. J Exp Med 2007; 204: 1441-51.
91. Urosevic M, Dummer R, Conrad C et al. Disease- independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97: 1143-53.
92. Panelli MC, Stashower ME, Slade HB et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo- controlled study defines the requirements for tissue rejection. Genome Biol 2007; 8: R8.
93. Harlin H, Meng Y, Peterson AC et al. Chemokine expression in melanoma metastases associated with CD8+ T- cell recruitment. Cancer Res 2009; 69: 3077-85.
94. Gabrilovich DI, Nagaraj S. Myeloid- derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
95. Menetrier- Caux C, Gobert M, Caux C. Differences in tumor regulatory T- cell localization and activation status impact patient outcome. Cancer Res 2009; 69: 7895-8.
96. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-94.
97. Antony PA, Piccirillo CA, Akpinarli A et al. CD8+ T cell immunity against a tumor/self- antigen Is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174: 2591-601.
98. Corthay A, Skovseth DK, Lundin KU et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22: 371-83.
99. + T cells eliminate MHC class II- negative cancer cells in vivo by indirect effects of IFN- γ. Proc Natl Acad Sci USA 1999; 96: 8633-8.
100. Quezada SA, Simpson TR, Peggs KS et al. Tumor- reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-50.
101. Xie Y, Akpinarli A, Maris C et al. Naive tumor- specific CD4+ T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207: 651-67.
102. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003; 300: 339-42.
103. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001; 182: 68-79.
104. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114: 1209-17.
105. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9.
106. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308.
107. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin- 10 and the interleukin- 10 receptor. Annu Rev Immunol 2001; 19: 683-765.
108. Terabe M, Matsui S, Noben- Trauth N et al. NKT cell- mediated repression of tumor immunosurveillance by IL- 13 and the IL- 4R- STAT6 pathway. Nat Immunol 2000; 1: 515-20.
109. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming Growth Factor- beta Regulation of Immune Responses. Annu Rev Immunol 2005; 24: 99-146.
110. Terabe M, Ambrosino E, Takaku S et al. Synergistic enhancement of CD8+ T cell- mediated tumor vaccine efficacy by an anti- transforming growth factor- beta monoclonal antibody. Clin Cancer Res 2009; 15: 6560-9.
111. Gabrilovich D. Mechanisms and functional significance of tumour- induced dendritic- cell defects. Nat Rev Immunol 2004; 4: 941-52.
112. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.
113. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA- 4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti- CTLA- 4 antibodies. J Exp Med 2009; 206: 1717-25.
114. Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010; 184: 3442-9.
115. Curran MA, Montalvo W, Yagita H, Allison JP. PD- 1 and CTLA- 4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107: 4275-80.
116. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23: 23-68.
117. Maus MV, Thomas AK, Leonard DG et al. Ex vivo expansion of polyclonal and antigen- specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T- cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20: 143-8.
118. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-61.
119. Itano AA, McSorley SJ, Reinhardt RL et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell- mediated immunity. Immunity 2003; 19: 47-57.